{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:44:13Z","timestamp":1784817853616,"version":"3.55.0"},"reference-count":13,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017239","name":"BeiGene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000555","name":"British Microcirculation Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2023,6,7]]},"DOI":"10.1080\/10428194.2023.2212433","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T01:39:30Z","timestamp":1684892370000},"page":"1243-1252","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"64","author":[{"given":"Jeff P.","family":"Sharman","sequence":"first","affiliation":[{"name":"Willamette Valley Cancer Institute and Research Center","place":["Eugene, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Miranda","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Roos","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugochinyere","family":"Emeribe","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Cai","sequence":"additional","affiliation":[{"name":"AstraZeneca, South San Francisco","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Liljas","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Gaitonde","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"Calquence [package insert]. Wilmington DE: AstraZeneca Pharmaceuticals; 2022."},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01485-x"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.1995.10476135"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00359-0"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2018.1434414"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199711000-00002"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.961012"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-005-1579-7"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S289139"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000771"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5381"},{"key":"e_1_3_3_14_1","article-title":"A quality-adjusted survival (Q-TWiST) analysis of acalabrutinib with or without obinutuzumab in patients with treatment-na\u00efve chronic lymphocytic leukemia [poster 1083755]","author":"Sharman JP","year":"2021","unstructured":"Sharman JP , Emeribe U , Cai L ,et\u00a0al. A quality-adjusted survival (Q-TWiST) analysis of acalabrutinib with or without obinutuzumab in patients with treatment-na\u00efve chronic lymphocytic leukemia [poster 1083755].Presented at: biennial International Workshop on Chronic Lymphocytic Leukemia.17\u201320 September 2021;","journal-title":"Presented at: biennial International Workshop on Chronic Lymphocytic Leukemia"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2023.2212433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:45:45Z","timestamp":1768207545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2023.2212433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,6,7]]}},"alternative-id":["10.1080\/10428194.2023.2212433"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2023.2212433","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}